Ann & Robert H Lurie Children's Hospital of Chicago

luriechildrens.org

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

177

Active

42

Phase 3

7

Total enrollment

40,612

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Recombinant Zoster Vaccine—————1
Combination therapy—————1
Trametinib and Nivolumab—————1
Dabrafenib, trametinib, nivolumab—————1
Tylenol—————1
Atropine—————1
Cytalux—————1
rHSC-DIPGVax—————1
Balstilimab—————1
Zalifrelimab—————1
Empagliflozin 10 MG—————1
trimethoprim-sulfamethoxazole—————1
Dose—————1

Next readouts

  • 2018-12
  • 2025-08-31
  • 2026-03-13
  • 2026-06-01
  • 2026-08-31
  • 2026-09
  • 2027-03-31
  • 2027-05
  • 2028-12
  • 2028-12-31

Top conditions

  • Sickle Cell Disease6
  • Eosinophilic Esophagitis6
  • Leukemia6
  • Cancer5
  • Sickle Cell Hemoglobin C4
  • Sickle Beta Zero Thalassemia4
  • Sickle B+ Thalassemia4
  • HIV4

Frequently asked questions about Ann & Robert H Lurie Children's Hospital of Chicago

How many clinical trials does Ann & Robert H Lurie Children's Hospital of Chicago have on ClinicalTrials.gov?
Ann & Robert H Lurie Children's Hospital of Chicago is listed as the lead sponsor on 177 clinical trials in ClinicalTrials.gov, 42 of which are currently active (recruiting, enrolling, or ongoing).
How many of Ann & Robert H Lurie Children's Hospital of Chicago's trials are in Phase 3?
7 of Ann & Robert H Lurie Children's Hospital of Chicago's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does Ann & Robert H Lurie Children's Hospital of Chicago focus on?
Ann & Robert H Lurie Children's Hospital of Chicago's most-studied conditions on ClinicalTrials.gov are Sickle Cell Disease, Eosinophilic Esophagitis, Leukemia, Cancer, Sickle Cell Hemoglobin C.
When are Ann & Robert H Lurie Children's Hospital of Chicago's next clinical trial readouts?
Ann & Robert H Lurie Children's Hospital of Chicago has 10 upcoming primary-completion readouts tracked here; the soonest is “Prophylactic Antibiotics or Placebo After Hypospadias Repair”, expected around 2018-12.